Announcing the BBCF Phase I Treatment Center

We would like to take this opportunity to introduce the opening of the BBCF Phase I Treatment Center.  The Center is housed on the 7th Floor of the Union Ave Office and will be staffed by Drs. Allen, Goorha, and Sachdev.  The Center has a dedicated research nurse and offers a complete line of service.

We are also very pleased to announce the opening of our first Phase I clinical trial:

A PHASE IB/II, MULTICENTER, TRIAL OF CVX-060, A SELECTIVE ANGIOPOIETIN-2 (ANG-2) BINDING, ANTI-ANGIOGENIC COVX-BODY, IN COMBINATION WITH SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

We are currently looking for potential participants for this study!

Appropriate candidates are those who:

- Have a histologically or cytologically confirmed
- advanced/metastatic solid tumor (does not have to be renal cell carcinoma) with measurable disease that is refractory to at least 1 line of systemic therapy
- Have ECOG PS of 0-1
- Do not have brain metastases
- Do not have any VEGF-related eligibility concerns

If you have a patient who you believe may be a good candidate, please send the patient's name and BBCF ID# to Debi Everts ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ).

Please keep in mind that due to the unique nature of Phase I trials, we will require patients to be seen and evaluated by a member of the Phase I team prior to offering enrollment.  Selected patients will need to follow with a physician member of the Phase I team throughout the duration of their participation in the Phase I trial.  Referring physicians will be kept abreast of any clinical developments.

Thanks for your support and please do not hesitate to contact us if there are any questions!

The Phase I Team